Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy

Clinical Genitourinary Cancer

Volumn 6, Issue 1, 2008, Pages 31-35

  Lassiter, Lance K ^a   Tummala, Mohan K ^b   Hussain, Maha H ^c   Stadler, Walter M ^d   Petrylak, Daniel P ^e   Carducci, Michael A ^f  

^a Matthews Hematology Oncology Associates   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d Hematology Oncology Section   (United States)

^e NewYork Presbyterian Columbia University Irving Medical Center   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antineoplastic activity; Myelosuppression; Pyrimidines; Second line therapy; Transitional cell carcinoma

Indexed keywords

PIRITREXIM;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLADDER CARCINOMA; BLEEDING; BONE MARROW SUPPRESSION; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DELIRIUM; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INTESTINE OBSTRUCTION; JAUNDICE; LEG EDEMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PATIENT ATTITUDE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; STATISTICAL ANALYSIS; THERAPY EFFECT; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINARY TRACT CARCINOMA; VOMITING; WEAKNESS;

EID: 43249097245     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.n.005     Document Type: Article

References (35)

1. PJ Loehrer Sr LH Einhorn PJ Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
2. CJ Logothetis FH Dexeus L Finn A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
3. A Bamias G Aravantinos C Deliveliotis Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group J Clin Oncol 22 2004 220 228
4. MJ Moore EW Winquist N Murray Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 2876 2881
5. V Lorusso L Manzione F De Vita Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial J Urol 164 2000 53 56
6. H von der Maase SW Hansen JT Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
7. BJ Roth DF Bajorin Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world J Urol 153 3 Pt 2 1995 894 900
8. CJ Sweeney BJ Roth FF Kabbinavar Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 24 2006 3451 3457
9. H von der Maase J Lehmann G Gravis A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium Ann Oncol 17 2006 1533 1538
10. EM Grivsky S Lee CW Sigel Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine J Med Chem 23 1980 327 329
11. DS Duch MP Edelstein SW Bowers Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase Cancer Res 42 1982 3987 3994
12. IW Taylor P Slowiaczek ML Friedlander Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake Cancer Res 45 1985 978 982
13. CW Sigel AW Macklin JL Woolley Jr Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase NCI Monogr 1987 111 120
14. J Laszlo WD Brenckman Jr E Morgan Initial clinical studies of piritrexim NCI Monogr 1987 121 125
15. GR Weiss GA Sarosy TD Shenkenberg A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U) Eur J Cancer Clin Oncol 25 1989 1867 1873
16. PC Adamson FM Balis J Miser Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule Cancer Res 50 1990 4464 4467
17. LG Feun N Savaraj P Benedetto Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies J Natl Cancer Inst 83 1991 51 55
18. PC Adamson FM Balis J Miser Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule Cancer Res 52 1992 521 524
19. R de Wit SB Kaye JT Roberts Oral piritrexim, an effective treatment for metastatic urothelial cancer Br J Cancer 67 1993 388 390
20. LG Feun N Savaraj P Benedetto Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy? Am J Clin Oncol 17 1994 448 451
21. M Khorsand J Lange L Feun Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder Invest New Drugs 15 1997 157 163
22. TR Fleming One-sample multiple testing procedure for phase II clinical trials Biometrics 38 1982 143 151
23. BJ Roth J Manola R Dreicer Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group Invest New Drugs 20 2002 425 429
24. LG Feun R Gonzalez N Savaraj Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration J Clin Oncol 9 1991 464 467
25. NM Bleehen HV Newman RP Rampling A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma Br J Cancer 72 1995 766 768
26. EG de Vries JA Gietema P Workman A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer Br J Cancer 68 1993 641 644
27. M Degardin C Domenge P Cappelaere A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck Eur J Cancer 30A 1994 1044 1045
28. LG Feun WA Robinson N Savaraj Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma Am J Clin Oncol 18 1995 488 490
29. MG Kris RJ Gralla MT Burke Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer Cancer Treat Rep 71 1987 763 764
30. JD Schiesel M Carabasi G Magill Oral piritrexim–a phase II study in patients with advanced soft tissue sarcoma Invest New Drugs 10 1992 97 98
31. WC Uen AT Huang R Mennel A phase II study of piritrexim in patients with advanced squamous head and neck cancer Cancer 69 1992 1008 1011
32. EE Vokes IW Dimery CD Jacobs A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer Cancer 67 1991 2253 2257
33. American Cancer Society Cancer Facts & Figures 2008 Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf Accessed: March 24, 2008
34. D Kaufman D Raghavan M Carducci Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 2000 1921 1927
35. CN Sternberg A Yagoda HI Scher Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse Cancer 64 1989 2448 2458